Accendatech’s leading portfolio drug is ACT001 that is currently in different stages of clinical study for multiple indications including brain metastasis, high grade gliomas such as DMG/DIPG and GBM and inflammatory diseases such as IPF/ILD and NMOSD.  ACT001 is the first-in-class therapeutics as a dual inhibitor targeting both the NF-κB and STAT3 pathways that are involved in many pathological processes.  The safety profile of ACT001 has been demonstrated by an array of clinical studies in adults and pediatric patients. ACT001 has been granted Orphan Drug Designation from US FDA and European Medicine Authority as brain tumor therapy.  It was also granted the Pediatric Rare Disease Designation and Fast Track Designation from FDA as a potential therapy for patients with DMG/DIPG.

      Accendatech is actively seeking partnership for co-development or licensing to accelerate the development of ACT001 that could benefit to patients globally.  Further business development discussion could be directed to  info@accendatech.com